Clinical Trial

A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary Aldosteronism

Name: A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary Aldosteronism — clinical trial record (NCT07646535)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a multicenter, randomized, double-blind, placebo-controlled phase II study designed to explore the efficacy and safety of different doses of SAL0140 in primary aldosteronism.

Trial Details

NCT Number	NCT07646535
Lead Sponsor	Shenzhen Salubris Pharmaceuticals Co., Ltd.
Conditions	Primary Aldosteronism
Enrollment	50 participants
Start Date	2026-06-12
Primary Completion	2027-04-01 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-12